{'fraction_non_alphanumeric': 0.023785926660059464, 'fraction_numerical': 0.002973240832507433, 'mean_word_length': 5.824324324324325, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Chemoprevention of cancer by organoselenium compounds

A major research goal of our laboratories is the development of new organoselenium cancer chemopreventive agents with less toxicity compared to some of the historical selenium compounds, such as sodium selenite. Ideally, such agents would be employed to inhibit tumor development in different organs caused by a variety of chemical carcinogens, particularly those present in the human environment. A series of organoselenium compounds has been synthesized and evaluated for their chemopreventive efficacy in vivo. Parallel to these studies, short‐term in vitro and in vivo assays were employed to understand the mechanism of action and to rapidly evaluate their efficacy in eventual long‐term preclinical investigations. We demonstrated that one of the most effective of these organoselenium compounds, 1,4‐phenylenebis(methylene)selenocyanate (p‐XSC, Fig. 1), is capable of inhibiting tumors in the mammary glands, colon, and lung of laboratory animals.